Medtronic plc, the global leader in medical technology, announced it will present new data on its MiniMed™ 780G system at the upcoming 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) in Amsterdam on March 19-22, 2025. Medtronic will address the challenges faced by women with diabetes. The company will also present clinical and real-world evidence of the MiniMed™ 780G system's effectiveness across diverse global populations, its use during exercise, its ability to achieve normoglycemia without giving rise to hypoglycemia, and integration with the Simplera Sync™ sensor.

• Empowering women with diabetes through AID technology: Real-world and clinical evidence will be presented to show the MiniMed™ 780G system’s ability to assist women with diabetes achieve glycemic outcomes, by adapting to hormonal changes during menstruation, and its use during pregestational diabetes^†. By helping to reduce some of the unique challenges faced by women living with diabetes, the MiniMed™ 780G system can potentially reduce the gender gap in diabetes care.
• Caring for children and adolescents with diabetes: Clinical evidence on the MiniMed™ 780G system will highlight the impact of use in younger populations shortly after diagnosis, and in at-risk youth with higher risks of poor glycemic outcomes. Medtronic intends to work with global regulators towards expanding access to its diabetes technology by including a lower age indication.
• The MiniMed™ 780G system is suitable for a broad range of users: Medtronic will build on existing real-world evidence across diverse Type 1 diabetes populations, showing that users are achieving glycemic outcomes regardless of location, culture or socioeconomic status.
• Time in Tight Range (TITR): Time in tight range of 70-140 mg/dL (3.9-7.8 mmol/L (also known as time in normoglycemia or time in the normal glycemic range) is emerging as an important new metric for monitoring the glycemic health of people with diabetes. An analysis of real-world data of over 140,000 users of the MiniMed™ 780G system demonstrates that time in range (TIR) of 70-180 mg/dl (3.9-10.0 mmol/l) is not necessarily correlated with improved TITR in those with a glucose management indicator (GMI) <7%. This means that both TIR and TITR should be evaluated in all people living with diabetes. In addition, there is no correlation with those achieving a GMI <6.5% with the development of hypoglycemia.

SCIENTIFIC DATA

The following poster and oral scientific data presentations represent the work of Medtronic employees and independent investigators using Medtronic devices in their research.

• A higher time in range cannot replace time in tight range as shown by real-world data from over 140,000 MiniMed™ 780G system users; oral presentation by Goran Petrovski, MD, PhD, Medical Affairs Director, Medtronic Diabetes, on Saturday March 22, 14:35-14:45 CET (8:35-8:45am CT) - Hall E
• Performance of the MiniMed™ 780G system in the Middle East, North Africa, and Turkey (MENAT) region: a real-world analysis of 7965 users; Short oral presentation by Dr. Mohammed Al-Sofiani, King Saud University, Saudi Arabia, on Thursday, March 20, 10:20-10:30am CET (4:20-4:30am CT) – Station 03
• Associations of CGM metrics with stimulated c-peptide measures in youth with recent-onset type 1 diabetes; oral presentation by Dr. Linda Anne DiMeglio, Riley Hospital for Children in Indianapolis, Indiana, USA, on Saturday March 22, 9:30-9:40 CET (3:30-3:40am CT) - Hall D2
• Impact of Simplera Sync™ sensors and extended infusion sets on glycemia and MiniMed 780G system performance in children and young adults with high HbA1c; oral presentation by Prof. Ben Wheeler, University of Otago, New Zealand, on Saturday March 22, 10:10-10:20 CET (4:10-4:20am CT) - Hall D1
• Automated insulin delivery is the gold standard in children and youth with type 1 diabetes and high-risk glycemia: results from the co-pilot randomized controlled trial; oral presentation by Dr. Alisa Boucsein, University of Otago, New Zealand, on Saturday March 22, 10:30-10:40 CET (4:30-4:40am CT) - Hall D1
• Predictors of glycemic improvement in children and youth with severe hyperglycemia using the MiniMed™ 780G system; oral presentation by Prof. Ben Wheeler, University of Otago, New Zealand, on Saturday March 22, 10:40-10:50 CET (4:40-4:50am CT) - Hall D1
• Achieving hypoglycemia targets with the MiniMed™ 780G system: largely independent of time in range and hyperglycemia targets in real-world use; e-poster viewing by Javier Castañeda, Senior Manager, Statistics, Medtronic Diabetes
• Glycemic control achieved by MiniMed™ 780G users with self-reported type 2 diabetes^† is sustainable for at least 6 months: a real-world analysis on 862 users; e-poster viewing by Vittorino Smaniotto, Senior Manager, Medical Affairs, Medtronic Diabetes
• The MiniMed™ 780G system provides glycemic control to both females and males: a real-world analysis of over 100,000 users; e-poster viewing by Jeremy Basset Sagarminaga, Medical Affairs Associate, Medtronic Diabetes
• First real-world results on the efficacy and safety of the Simplera Sync™ sensor in MiniMed™ 780G system users in Europe; e-poster viewing by John Shin, Ph.D., MBA, Senior Clinical Research Director, Medtronic Diabetes
• Changes in body mass index in persons with type 1 diabetes mellitus using the MiniMed™ 780G AID system; e-poster viewing by Pim Dekker PhD, Diabeter Netherlands, Centre for Pediatric and Adult Diabetes Care and Research, Rotterdam, The Netherlands
• Late-breaking: Bridging the gap: socioeconomic status, educational level and glycemic control in Colombian users of the MiniMed™ 780G system; e-poster viewing by Ana Maria Gómez, Professor MD PhD, Hospital Universitario San Ignacio, Bogota, Colombia and Matias Castro, Principal Medical Science Liaison Specialist, Medtronic Diabetes, LATAM
• Impact of early initiation of automated insulin delivery on glycemia two years from onset of type 1 diabetes; e-poster viewing by Michelle Van Name, MD, Associate Professor of Pediatrics (Endocrinology) Yale University School of Medicine, USA
• Fast-acting insulin ASPART in adults using an advanced hybrid closed loop system; e-poster viewing by Noga Minsky, MD, Sheba Medical Centre, Tel Aviv, Israel      
• Mitigation strategies for a missed meal bolus in people with type 1 diabetes using the MiniMed™ 780G system; e-poster viewing by Prof. Bruno Grassi MD, Nutrition, Diabetes and Metabolism unit, Pontificia Universidad Católica de Chile             
• Impact of Simplera Sync™ sensors and extended infusion sets on children and young adults using MiniMed 780G: a qualitative study; e-poster viewing by Michelle Van Name, MD, Associate Professor of Pediatrics (Endocrinology) Yale University School of Medicine, USA

MEDTRONIC SPONSORED EVENTS

Medtronic Symposium: Bridging the gender gap in diabetes care with the MiniMed™ 780G AID system. Thursday, March 20, at 10:30-12:00 CET (4:30-6:00am CT), Hall A, chaired by Dr. Sarah Siegelaar, Department of Internal Medicine, Endocrinology and Metabolism, Amsterdam UMC and Diabeter Centrum Amsterdam, the Netherlands, and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes.

MEDTRONIC WORKSHOPS

• “The Smart MDI system – maximizing the benefits of its unique features” chaired by Madison Smith, PhD, Smart MDI Therapy Chief Engineer, Medtronic Diabetes and Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes, with speakers Amy Jolley MSc, BSc, RD, Lead Diabetes Specialist Dietitian, Salford Hospital, United Kingdom Dr. Peter Adolfsson MD, PhD, Högsbo Hospital, Gothenburg (adults) and the Hospital of Halland, Kungsbacka (children), Sweden  and Prof. Goran Petrovski, Medical Affairs Director, Medtronic Diabetes on Thursday, March 20, 13:00-14:30 CET (7:00-8:30am CT), Hall I.
• “Maximizing outcomes with the MiniMed™ 780G system for different people with diabetes (PWD) profiles in their daily life and exercise”, chaired by Prof. Ohad Cohen, MD, Senior Global Medical Affairs Director, Medtronic Diabetes with speakers Prof. Goran Petrovski, Medical Affairs Director, Medtronic Diabetes, Dr. Martin Cuesta, Hospital Clínico San Carlos in Madrid, Spain, Assoc. Prof. Klemen Dovč, University Medical Center Ljubljana, Slovenia and Dessi Zaharieva PhD, CEP, CDCES, Stanford Medicine, USA on Friday, March 21, 09:30-10:45 CET (3:30-4:45-am CT), Hall I.

About Medtronic Diabetes (www.medtronicdiabetes.com)
Medtronic Diabetes is on a mission to alleviate the burden of diabetes by empowering individuals to live life on their terms, with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

^†The MiniMed™ 780G system has not been approved for use in pregnancy or type 2 diabetes by U.S. FDA or other regulatory bodies.  

Contacts:
Ashley Patterson
Global Communications
+1-818-576-3025

Ryan Weispfenning
Investor Relations
+1-763-505-4626